title: Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin.
abstract: The in vitro activity of tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin was tested against 63 clinical isolates of Ureaplasma urealyticum. The minimal inhibitory concentrations (MICs) and the minimal bactericidal concentrations (MBCs) were determined by the broth microdilution method in A7 medium. The MIC(50) and MIC(90) of the tested agents after 24 h of incubation were as follows: tetracycline, 0.5 and 2.0 μg/ml; doxycycline, 0.125 and 0.25 μg/ml; erythromycin, 2.0 and 8.0 μg/ml; roxithromycin, 2.0 and 4.0 μg/ml; clarithromycin, 0.25 and 1.0 μg/ml; azithromycin, 2.0 and 4.0 μg/ml; levofloxacin, 1.0 and 2.0 μg/ml; and moxifloxacin, 0.5 and 0.5 μg/ml, respectively. The MIC values after 24 h and 48 h incubation differed by no more than one dilution for all the agents with the exception of doxycycline (two dilution difference for MIC(90)). Overall, moxifloxacin was the most active agent in vitro against U. urealyticum, with the narrowest difference between MIC and MBC values, followed closely by levofloxacin. Clarithromycin was the most active macrolide.
authors.affiliation: Chlamydia and Mycoplasma National Center, Department of Microbiology, Rabin Medical Center, Beillinson Campus, Petah Tikva, Israel.
authors.forename: Z
authors.initials: Z
authors.lastname: Samra
authors.forename: S
authors.initials: S
authors.lastname: Rosenberg
authors.forename: M
authors.initials: M
authors.lastname: Dan
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001372:Aza Compounds / Q000494:pharmacology; D017963:Azithromycin / Q000494:pharmacology / Q000627:therapeutic use; D017291:Clarithromycin / Q000494:pharmacology / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004318:Doxycycline / Q000494:pharmacology / Q000627:therapeutic use; D004917:Erythromycin / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D015242:Ofloxacin / Q000494:pharmacology / Q000627:therapeutic use; D011804:Quinolines / Q000494:pharmacology; D015203:Reproducibility of Results; D015575:Roxithromycin / Q000494:pharmacology / Q000627:therapeutic use; D013752:Tetracycline / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors; D016869:Ureaplasma Infections / Q000188:drug therapy*; D016990:Ureaplasma urealyticum / Q000187:drug effects*
chemical_list: D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D015575:Roxithromycin; D004917:Erythromycin; D064704:Levofloxacin; D017963:Azithromycin; D015242:Ofloxacin; D013752:Tetracycline; D017291:Clarithromycin; D004318:Doxycycline; D000077266:Moxifloxacin